Novoste hopes to win the commercial race to develop radiation treatment for restenosis
This article was originally published in Clinica
Executive Summary
For three decades radiation has been known to prevent restenosis. Companies have taken differing routes to achieve market leadership in a sector estimated to be worth between $500 million and $600 million in 2001. Analysts at Piper Jaffray say that Novoste has the most promise, but Johnson & Johnson could be the first on the US market.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.